Compare HNNA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNNA | ATOS |
|---|---|---|
| Founded | 1989 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 83.3M |
| IPO Year | N/A | 2012 |
| Metric | HNNA | ATOS |
|---|---|---|
| Price | $10.00 | $4.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.67 |
| AVG Volume (30 Days) | 19.1K | ★ 256.9K |
| Earning Date | 02-05-2026 | 03-24-2026 |
| Dividend Yield | ★ 5.47% | N/A |
| EPS Growth | ★ 2.51 | N/A |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $34,150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | ★ 2.83 | N/A |
| 52 Week Low | $8.43 | $3.76 |
| 52 Week High | $13.19 | $19.35 |
| Indicator | HNNA | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 65.41 |
| Support Level | $9.72 | $3.76 |
| Resistance Level | $10.27 | $5.54 |
| Average True Range (ATR) | 0.37 | 0.48 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 38.58 | 49.34 |
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.